Home/Pipeline/MT-40x

MT-40x

Tumor‑targeting antibodies for solid tumors

PreclinicalActive

Key Facts

Indication
Tumor‑targeting antibodies for solid tumors
Phase
Preclinical
Status
Active
Company

About MabTics

Innovative antibody platform focused on vessel normalization for oncology, vascular, and eye diseases.

View full company profile